Lack of rapid virological response predicts interferon-α2b/ribavirin therapy failure in HCV genotype 2 patients: A single-centre study

Antiviral Therapy

Volumn 12, Issue 7, 2007, Pages 1033-1040

  Rumi, Maria Grazia ^a   Aghemo, Alessio ^a   D'Ambrosio, Roberta ^a   Ronchi, Guido ^a   Del Ninno, Ersilio ^a   Gallus, Silvano ^b   Colombo, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; RNA;

ADULT; AGE; AGED; ARTICLE; ASTHENIA; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GENOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUTROPENIA; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD;

EID: 36148981111     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36:S35-S46.
2. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
3. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492.
4. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
6. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-355.
7. Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006; 11:797-802.
8. Dalgard O, Bjoro K, Helium KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40:1260-1265.
9. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
10. Von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40kD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-527.
11. Andriulli A, Dalgard O, Bjoro K, Mangia A. Short-term treatment duration for HCV-2 and HCV-3 infected patients. Dig Liver Dis 2006; 38:741-748.
12. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 vs 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2006; 56:553-539.
13. Osella AR, Sonzogni L, Cavallini A, et al. Molecular epidemiology of hepatitis C virus infection in an area of hyperendemicity in southern Italy: a population-based study. J Clin Microbiol 1999; 37:2371-2372.
14. Cenci M, De Soccio G, Recchia O. Prevalence of hepatitis C virus (HCV) genotypes in central Italy. Anticancer Res 2003; 23:5129-5132.
15. Rumi MG, De Filippi F, La Vecchia C, et al. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54:402-406.
16. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 June 10-12. Hepatology 2002; 36:S3-S20.
17. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:225-230.
18. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
19. Soffredini R, Rumi MG, Parravicini ML, et al. Serum levels of hepatitis C virus core antigen as a marker of infection and response to therapy. Am J Gastroenterol 2004; 99:1738-1743.
20. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696-699.
21. Gluud C. The culture of designing hepato-biliary randomised trials. J Hepatology 2006; 44:607-615.
22. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40:993-999.
23. Feld JJ, Hopfnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005; 436:967-972.
24. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5:85-90.
25. Zeuzem S, Hermann E, Lee JH, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterologe 2001; 120:1438-1447.
26. Shiffman ML, Pappas S, Nyberg L, et al. Peginterferon alpha-2a (Pegasys) plus ribavirin (Copegus) for 16 or 24 weeks in patients with HCV genotype 2 or 3. Final results of the accelerate trial. J Hepatol 2006; 44:S271.
27. Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin. J Hepatol 2005; 42:275-276.
28. Sarrazin C, Gartner BC, Sizmann D, et al. Comparison of conventional PCR with real-time PCR and branched DNA-based assays for hepatitis C virus RNA quantification and clinical significance for genotypes 1 to 5. J Clin Microbiol. 2006; 44:729-737.